The good news is here, the House voted 296-121 Friday to pass a $915-billion spending package to fund the federal government for the rest of the fiscal year, likely staving off a threatened midnight government shutdown. Now we have to hear from the Senate to be sure that the Prostate Cancer Research Program in the [...]
I woke up this morning to some potentially good news. Last night the congressional committee finalized their reconciliation report and filed the final FY12 Omnibus Report. I am over joyed to report that the Report included the Peer Reviewed Compressional Directed Medical Research Programs that had become the target of budget cutters. Many of us [...]
On September 15, the Senate Committee on Appropriations approved their FY12 report by a vote of 30-0. Included in the report was their recommendations for the Department of Defense Research Programs. […]
We dodged a bullet… for now! I’m pleased to report that the House just approved the FY12 DoD Appropriations Bill by a vote of 331-83. No amendments were offered to reduce or eliminate CDMRP (the Department of Defense Medical Research Program) funding. At this time we have managed to maintain the funding for the Prostate [...]
Yesterday there was an amendment passed on the House floor to restore the Prostate Cancer Research Program's 2012 funding to $80 million. The Department of Defense (DoD) Appropriations Bill (H.R. 2219) originally was slated to allocate only $64 million to the Prostate Cancer Research Program (PCRP), a 20% reduction from last year’s funding. Restoring these [...]
YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]
From Anthony Hardie, Madison, Wis. All: I've just gone through the full Defense Committee bill (before yesterday's markup) and the corresponding report language on the various CDMRP programs. The results are below. FY12 Defense Appropriations -- Full Committee Bill (before yesterday's markup): 1. Several programs would not be funded at all: most notably the sort [...]
U.S. SENATE: Save the Prostate Cancer Research Program Now it is time to write your U.S. Senators - TODAY! A few weeks ago I requested that you write to your member of the House of Representatives, now it is time to write to the other side of congress, the Senate. Write your U.S. Senators today [...]
Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved [...]
The long awaited FDA approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy has happened! Malecare celebrates this approval as it celebrates the significant numbers of new drug approvals we have had over the last year and one half. The approval of Zytiga represents [...]
